GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) | ENROLLING NOW
Patients in the GESTALT Clinical Trial benefit from immediate radiation treatment at the completion of their brain tumor removal surgery, plus the Stupp protocol standard of care. Studies show that earlier radiation treatment may be more effective than later treatment.1,2
The GESTALT Clinical Team will closely monitor your care. And you’ll be making a valuable contribution to future patients, helping to provide more information about how starting radiation immediately, instead of waiting, can improve outcomes
The GESTALT Trial is sponsored by GT Medical Technologies, Inc., the makers of GammaTile®. Please discuss the risks and benefits of participating in this clinical trial with your care team.
Indication: GammaTile is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
Safety Information: The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials.
GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs)
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.